Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.22.1
Summary of Significant Accounting Policies (Details Narrative)
 12 Months Ended
Nov. 19, 2021
ft²
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Defined Benefit Plan Disclosure [Line Items]      
Net loss   $ 58,013,000 $ 28,296,000
Non-cash stock compensation   33,900,000  
Cash in Operating activities   15,606,000 7,262,000
Cash and short-term investments   32,000,000.0  
Working capital and stockholders' equity   22,900,000  
Cash and investments   32,000,000.0  
Proceeds from issuance of common stock   24,679,000
Proceeds from exercise of warrants   16,433,000
Proceeds from issuance of convertible notes   1,200,000  
Derivative liability   138,000 $ 383,000
FDIC amount   250,000  
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs   4,500,000  
Aimmune Therapeutics Inc [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Office space | ft² 4,500    
Sublease maturity, description commencement date of January 1, 2022 and maturing on June 30, 2024    
Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Derivative liability   $ 100,000